X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US

    Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US

    Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

    CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine. Candidate, CV2CoV

    Stevanato Group Launches After-sales Service Offering

    Stevanato Group to Create Manufacturing Hub in China

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    Takara Bio and Boston IVF Fertility Center Announce Partnership to Enable the Derivation of Clinical-grade hES cell lines for Cell Therapy Applications

    Calyx Selected by ProTrials as Partner for Improving Clinical Trial Outcomes Data

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US

    Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US

    Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

    CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine. Candidate, CV2CoV

    Stevanato Group Launches After-sales Service Offering

    Stevanato Group to Create Manufacturing Hub in China

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

    Takara Bio and Boston IVF Fertility Center Announce Partnership to Enable the Derivation of Clinical-grade hES cell lines for Cell Therapy Applications

    Calyx Selected by ProTrials as Partner for Improving Clinical Trial Outcomes Data

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Amphista and BMS partner to develop protein degradation therapies

Content Team by Content Team
6th May 2022
in News
Thermo Fisher Announces Agreement with Advanced Electrophoresis Solutions to Accelerate Therapeutic Development through Cutting-Edge Protein Analysis

Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, today announced a strategic collaboration with Merck Healthcare, a division of Merck. Under the terms of the agreement, Merck and Amphista will work collaboratively to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology indications. Amphista will receive an upfront payment, R&D funding and success-based milestone payments of up to €893.5 million ($1.0 billion*) as well as royalties in the mid-single digit range. Completion of the transaction is subject to the parties obtaining any necessary regulatory clearances or approvals.

Nicola Thompson, CEO of Amphista, said, “We are extremely pleased to enter into this collaboration with Merck. This is a significant validation of the progress we have made in TPD research and the potential of our Eclipsys next-generation TPD platform. We look forward to working with the Merck team, using our combined expertise to develop new TPD therapies to treat cancers and immuno-inflammatory diseases.”

TPD therapies are designed to use physiological mechanisms to remove pathogenic protein from the body, offering the potential to access many disease targets previously considered “undruggable.” Amphista’s technology is specifically designed to develop next generation TPD therapeutics based on mechanistic insights and novel chemistry approaches that enable the company to develop novel protein degrading therapeutics with superior levels of efficacy and broad therapeutic applicability.

Previous Post

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

Related Posts

Catalent To Open New Clinical Supply Facility In San Diego
News

Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech

6th May 2022
Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
News

Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells

6th May 2022
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility
News

Tweaks In Booster Pitch By Moderna Before Fall Approaches

6th May 2022
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
News

FDA Expects COVID Vaccines To Become An Annual Occurrence

6th May 2022
Indian Pharmaceutical Industry In 2021 And The Road Ahead
News

Despite Global Issues, Indian Pharma Exports Remain Strong

6th May 2022
As Per WHO Omicron To Affect Above 50% of Europe In 2 Months
News

Newer Omicron Types Initiate Their Own Coronavirus Waves

4th May 2022

Latest News

Thermo Fisher Announces Agreement with Advanced Electrophoresis Solutions to Accelerate Therapeutic Development through Cutting-Edge Protein Analysis
News

Amphista and BMS partner to develop protein degradation therapies

6th May 2022
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
Drug Development

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

6th May 2022
Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility
Press Statements

Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility

6th May 2022
Catalent To Open New Clinical Supply Facility In San Diego
News

Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech

6th May 2022
Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
News

Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells

6th May 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In